Table 2
Evolution of the patients’ functional status by New York Heart Association functional class
Time point
Trimetazidine group
Control group
I
II
III
IV
Total
I
II
III
IV
Total
Baseline
0
11
17
2
30
0
10
18
3
31
6 months
1
11
16
2
30
0
10
17
4
31
12 months
4
20
4
0
28
0
2
23
4
29
18 month
4
21
1
0
26
0
1
24
3
28